Updated 2023 GOLD Report Revises COPD Definitions and …
The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
GOLD COPD Report 2025: Key Spirometry and Drug Updates
Nov 22, 2024 · The 2025 GOLD COPD report includes a new emphasis on CV disease and PH in COPD and major updates on spirometry, new COPD drugs, climate change, and more. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released its 2025 updated version of the GOLD Chronic Obstructive Pulmonary Disease (COPD) report earlier this month, just in ...
Tezepelumab Gets Breakthrough Therapy Status for COPD Tx
Aug 12, 2024 · The primary endpoint was COPD exacerbation rate. Findings showed in the overall population, treatment with tezepelumab led to a 17% reduction (90% CI, -6, 36; P =.1042) in the annual rate of moderate to severe COPD exacerbations compared with placebo (annualized rate of exacerbations: 1.75 with tezepelumab vs 2.11 with placebo).
2024 GOLD Report Reflects New Research on COPD Management
Dec 8, 2023 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...
Real-World COPD Medication Use Appears Consistent With GOLD ...
Dec 12, 2023 · Investigators analyzed patient data from the COSYNET trial (COPD and Systemic Consequences – Comorbidities Network; ClinicalTrials.gov Identifier: NCT01245933) to determine factors associated with real-world COPD medication use. The COSYCONET trial is an ongoing, noninterventional COPD study conducted at in 31 centers across Germany.
Breathing New Life Into COPD and Asthma Therapy With Statins
A year later, Chinese researchers found in a meta-analysis of 15 studies comprising 238,459 patients that statins had a beneficial effect on COPD. 3 Statins reduced all-cause mortality by 38% (95% CI, 0.52-0.73) and COPD mortality by 52% (95% CI, 0.23-0.99). 3 Of the 15 studies, 6 showed that statins reduced the risk for COPD exacerbations by ...
GINA 2024 Asthma Update: Revised Recommendations on …
Jun 28, 2024 · Also, a new section has been provided on preventing occupational asthma in adults, as 5% to 20% of new cases of adult-onset asthma may be attributed to occupational exposure. Patients who have suspected or confirmed occupational asthma should be referred for expert assessment owing to the economic and legal implications, according to the committee.
Can Digital Tools for COPD Self-Management Improve Patient …
Dec 2, 2022 · To learn more about the application of digital tools in COPD treatment and self-management, we interviewed Brian D. Gelbman, MD, clinical associate professor in the division of pulmonary and critical care medicine at Weill Cornell Medical College in New York and author of the previously referenced 2022 study of COPD self-management tools 2, and ...
Dupixent Approved as Add-On Maintenance Therapy in COPD
Oct 1, 2024 · The primary endpoint was the annualized rate of moderate or severe COPD exacerbations over 52 weeks. Trial results showed patients treated with dupilumab saw a 30% reduction (BOREAS trial) and a 34% reduction (NOTUS trial) in the annualized rate of moderate or severe COPD exacerbations compared with placebo.
FDA Alert: Pulmonology Device, Drug Approvals and Recalls
Sep 20, 2024 · Dupilumab treatment vs placebo reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial. 7. Medication Class: Interleukin-4 receptor alpha antagonist; Dosing: 300 mg every other week in COPD; note that dosing differs for other indications. Administer by subcutaneous injection ...